THE SIGNIFICANCE OF NATRIURETIC PEPTIDES AND NEPRILYSIN INHIBITORS IN THE DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR DISEASES
Keywords:
Natriuretic peptides; atrial natriuretic peptide; B-type natriuretic peptide; NT-proBNP; neprilysin; sacubitril/valsartan; heart failure; cardiovascular disease.Abstract
Background: Natriuretic peptides are central components of the cardiovascular endocrine response to myocardial wall stress. Atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), and N-terminal pro-B-type natriuretic peptide (NT-proBNP) connect pathophysiology, diagnosis, prognosis, and treatment of heart failure (HF). Neprilysin degrades several vasoactive peptides, including natriuretic peptides; therefore, inhibition of neprilysin, combined with angiotensin II type 1 receptor blockade, provides a rational therapeutic strategy. Objective: To review the diagnostic and prognostic value of natriuretic peptides and to assess the role of neprilysin inhibition, particularly sacubitril/valsartan, across the spectrum of HF. Methods: A narrative review was conducted using major randomized trials, international HF guidelines, a joint scientific statement on natriuretic peptides, and regulatory prescribing information. Results: BNP and NT-proBNP are useful for ruling out HF, supporting diagnosis, estimating prognosis, and establishing a baseline for follow-up, although age, atrial fibrillation, renal dysfunction, obesity, and treatment modify interpretation. In HFrEF, sacubitril/valsartan reduced cardiovascular death or HF hospitalization compared with enalapril in PARADIGM-HF. After stabilization from acute decompensated HFrEF, in-hospital initiation produced a greater NT-proBNP reduction than enalapril in PIONEER-HF. Evidence in HFmrEF and HFpEF is more heterogeneous; benefit appears concentrated toward the lower ejection-fraction range and in selected patients. Conclusions: Natriuretic peptides and neprilysin inhibition represent complementary diagnostic and therapeutic applications of the same biological pathway. NT-proBNP is generally preferred for biomarker monitoring during sacubitril/valsartan therapy because BNP is a neprilysin substrate and may rise or change unpredictably after treatment initiation. Clinical decisions must integrate peptide concentrations with symptoms, examination, electrocardiography, imaging, comorbidity, blood pressure, kidney function, and serum potassium.
References
1.DE BOLD A. J., BORENSTEIN H. B., VERESS A. T., SONNENBERG H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats // Life Sciences. - 1981. - Vol. 28, no. 1. - P. 89-94. - DOI: 10.1016/0024-3205(81)90370-2.
2.DESAI A. S., SOLOMON S. D., SHAH A. M. et al. Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial // JAMA. - 2019. - Vol. 322, no. 11. - P. 1077-1084. - DOI: 10.1001/jama.2019.12843.
3.DOCHERTY K. F., VADUGANATHAN M., SOLOMON S. D., MCMURRAY J. J. V. Sacubitril/valsartan: neprilysin inhibition 5 years after PARADIGM-HF // JACC Heart Failure. - 2020. - Vol. 8, no. 10. - P. 800-810. - DOI: 10.1016/j.jchf.2020.06.020.
4.ENTRESTO (sacubitril and valsartan) tablets: prescribing information [Electronic resource] / U.S. Food and Drug Administration. - 2024. - URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/207620s026lbl.pdf (accessed: 13.09.2026).
5.HEIDENREICH P. A., BOZKURT B., AGUILAR D. et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure // Circulation. - 2022. - Vol. 145, no. 18. - P. e895-e1032. - DOI: 10.1161/CIR.0000000000001063.
6.MCDONAGH T. A., METRA M., ADAMO M. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure // European Heart Journal. - 2021. - Vol. 42, no. 36. - P. 3599-3726. - DOI: 10.1093/eurheartj/ehab368.
7.MCDONAGH T. A., METRA M., ADAMO M. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: supplementary data // European Heart Journal. - 2021. - Vol. 42, no. 36. - DOI: 10.1093/eurheartj/ehab368.
8.MCDONAGH T. A., METRA M., ADAMO M. et al. 2023 focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure // European Heart Journal. - 2023. - Vol. 44, no. 37. - P. 3627-3639. - DOI: 10.1093/eurheartj/ehad195.
9.MCMURRAY J. J. V., PACKER M., DESAI A. S. et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure // The New England Journal of Medicine. - 2014. - Vol. 371, no. 11. - P. 993-1004. - DOI: 10.1056/NEJMoa1409077.
10.MENTZ R. J., WARD J. H., HERNANDEZ A. F. et al. Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure // Journal of the American College of Cardiology. - 2023. - Vol. 82, no. 1. - P. 1-12. - DOI: 10.1016/j.jacc.2023.04.019.
11.MENTZ R. J., WARD J. H., HERNANDEZ A. F. et al. Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction after worsening heart failure: pooled analysis of PARAGLIDE-HF and PARAGON-HF // European Heart Journal. - 2023. - Vol. 44, no. 31. - P. 2982-2993. - DOI: 10.1093/eurheartj/ehad359.
12.SANGARALINGHAM S. J., KUHN M., CANNONE V., CHEN H. H., BURNETT J. C. Natriuretic peptide pathways in heart failure: further therapeutic possibilities // Cardiovascular Research. - 2023. - Vol. 118, no. 18. - P. 3416-3433. - DOI: 10.1093/cvr/cvac125.
13.SOLOMON S. D., MCMURRAY J. J. V., ANAND I. S. et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction // The New England Journal of Medicine. - 2019. - Vol. 381, no. 17. - P. 1609-1620. - DOI: 10.1056/NEJMoa1908655.
14.SOLOMON S. D., MCMURRAY J. J. V., ANAND I. S. et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure // Circulation. - 2020. - Vol. 141, no. 5. - P. 352-361. - DOI: 10.1161/CIRCULATIONAHA.119.044586.
15.TSUTSUI H., ALBERT N. M., COATS A. J. S. et al. Natriuretic peptides: role in the diagnosis and management of heart failure: a scientific statement from the HFA of the ESC, HFSA and JHFS // European Journal of Heart Failure. - 2023. - Vol. 25, no. 5. - P. 616-631. - DOI: 10.1002/ejhf.2848.
